B
Bull
Bull · 25%ONCO
$4.05
Precio del escenario
$0.612
-0.019 (-3.12%)Al cierre
Loading chart…
- High
- 0.644
- Open
- 0.628
- VWAP
- 0.62
- Vol
- 91.48K
- Mkt Cap
- —
- Low
- 0.610
- Amount
- 56.90K
- EV/EBITDA, TTM
- 0.00
Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.
AI analysis of Onconetix Inc (ONCO)
sellOnconetix Inc (ONCO) is not a good buy right now due to its extremely low current price of $0.61, a year-to-date change of -99.24%, and a very low RSI of 16.50, indicating oversold conditions. The company has also reported significant losses, with a net income of -2,867,303 in Q2 2026 and a gross margin of only 25.13%. The primary risk is the potential for further declines given the stock's volatility and the recent reverse stock split aimed at maintaining compliance with Nasdaq listing requirements.
Métricas de valoración
The current forward P/E ratio for Onconetix Inc (ONCO) is 0.00, compared to its 5-year average forward P/E of -2.37.
Alphio AI Price Scenarios for ONCO
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Cronología de eventos
Noticias
9.508-27Yahoo FinanceOncopeptides Reports Strong Q2 2026 Earnings Growth
8.508-06GlobenewswireOnconetix Advances Acquisition of Realbotix Amid Humanoid Robotics Adoption
5.008-05GlobenewswireProteomedix Appoints Ralph Schiess to Board
5.008-05NewsfilterProteomedix Appoints Ralph Schiess to Board
8.506-26GlobenewswireNext-Generation DNA Repair Therapies Open New Frontiers in Oncology
ONCO FAQ — answered by Alphio AI
Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Onconetix Inc (ONCO) is not a good buy right now due to its extremely low current price of $0.61, a year-to-date change of -99.24%, and a very low RSI of 16.50, indicating oversold conditions. The company has also reported significant losses, with a net income of -2,867,303 in Q2 2026 and a gross margin of only 25.13%. The primary risk is the potential for further declines given the stock's volatility and the recent reverse stock split aimed at maintaining compliance with Nasdaq listing requirements.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.